Medicare Pilot Offers GLP‑1 Discount, Excludes Most Seriously Ill

Medicare has launched a pilot program that streamlines access to GLP‑1 drugs, a class used for diabetes and weight management, and offers some seniors a monthly cost of $50. The initiative is designed to reduce prescription costs for eligible beneficiaries. However, the eligibility criteria exclude patients with the most serious illnesses, meaning those who may need the medication most cannot benefit from the discount. The program remains in a trial phase, and Medicare will assess uptake and impact before deciding whether to expand the discount to a broader population.